Introduction: Intravitreal anti-VEGF is the most effective therapy for wet AMD, although systemic effects on the endothelium cannot be excluded. Areas covered: The purpose of this review was to evaluate risk of thromboembolic events associated with intravitreal anti-VEGF. Expert opinion: Current data are insufficient to confirm the safety of these compounds, due to the paucity of specific studies. Thus, pharmacovigilance for all anti-VEGF should be improved to verify the true role of anti-VEGF in the occurrence of systemic adverse events.
Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update / Costagliola, Ciro; Morescalchi, Francesco; Duse, Sarah; Romano, Davide; Mazza, Giuseppina; Parmeggiani, Francesco; Bartollino, Silvia; Semeraro, Francesco. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2019). [10.1080/14740338.2019.1643838]
Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update
Costagliola, Ciro;
2019
Abstract
Introduction: Intravitreal anti-VEGF is the most effective therapy for wet AMD, although systemic effects on the endothelium cannot be excluded. Areas covered: The purpose of this review was to evaluate risk of thromboembolic events associated with intravitreal anti-VEGF. Expert opinion: Current data are insufficient to confirm the safety of these compounds, due to the paucity of specific studies. Thus, pharmacovigilance for all anti-VEGF should be improved to verify the true role of anti-VEGF in the occurrence of systemic adverse events.File | Dimensione | Formato | |
---|---|---|---|
2019_Systemic thromboemolitic.pdf
non disponibili
Dimensione
552.94 kB
Formato
Adobe PDF
|
552.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.